key: cord-0026734-cnku7fs3
authors: Liu, Zhenfeng; Liu, Daishun; Wang, Zhihua; Zou, Yugang; Wang, Haixia; Li, Xiao; Zheng, Deliang; Zhou, Guoqi
title: Association between inflammatory biomarkers and acute respiratory distress syndrome or acute lung injury risk: A systematic review and meta-analysis
date: 2021-12-03
journal: Wien Klin Wochenschr
DOI: 10.1007/s00508-021-01971-3
sha: df271eb8d7c2501063070f20e1b164b780fac023
doc_id: 26734
cord_uid: cnku7fs3

BACKGROUND: The relationship between acute respiratory distress syndrome (ARDS)/acute lung injury (ALI) and levels of certain inflammatory factors remains controversial. The purpose of this meta-analysis was to summarize the available studies evaluating the association between levels of inflammatory factors and ARDS/ALI incidence. METHODS: We searched the PubMed, EmBase, and Cochrane databases for studies published up to July 2017. For each inflammatory factor, a random effects model was employed to pool results from different studies. RESULTS: We identified 63 studies that included 6243 patients in our meta-analysis. Overall, the results indicated that the levels of angiopoietin (ANG)-2 (standard mean difference, SMD: 1.34; P < 0.001), interleukin (IL)-1β (SMD: 0.92; P = 0.012), IL‑6 (SMD: 0.66; P = 0.005), and tumor necrosis factor (TNF)-α (SMD: 0.98; P = 0.001) were significantly higher in patients with ARDS/ALI than in unaffected individuals. No significant differences were observed between patients with ARDS/ALI and unaffected individuals in terms of the levels of IL‑8 (SMD: 0.61; P = 0.159), IL-10 (SMD: 1.10; P = 0.231), and plasminogen activator inhibitor (PAI)-1 (SMD: 0.70; P = 0.060). CONCLUSIONS: ARDS/ALI is associated with a significantly elevated levels of ANG‑2, IL-1β, IL‑6, and TNF‑α, but not with IL‑8, IL-10, and PAI‑1 levels. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00508-021-01971-3) contains supplementary material, which is available to authorized users.

poxemia, and accumulation of bilateral pulmonary infiltrates [1] . In the USA the annual number of ARDS cases is more than 140,000 [2] and the reported rates of ARDS and ALI are 59 and 79 cases for every 100,000 individuals, respectively, with reported mortality rates ranging from 22% to 41% [3] . ARDS and ALI are triggered by several factors that are associated with either direct or indirect injury. Direct injuries that trigger ARDS/ALI include serious pulmonary infection, aspiration of foreign bodies, pulmonary contusion, and oxygen poisoning. Indirect injuries associated with ARDS/ALI include severe systemic infection, severe non-pulmonary trauma, acute pancreatitis, major blood transfusion, and disseminated intravascular coagulation [4, 5] . Patients exposed to the abovementioned factors are at high risk for developing ARDS/ALI. Although the mechanisms underlying ARDS/ALI pathogenesis remain unclear, inflammation has been considered as one of the major inducing factors.

The pathology of ARDS is characterized by diffuse pulmonary interstitial and alveolar edema due to capillary endothelial and alveolar epithelial cell injuries that lead to acute respiratory insufficiency or failure [6] . In the early stages of ARDS, edema fluid is concentrated in the alveolar interstitial spaces, and neutrophils adhere to the surface of damaged vascular endothelial cells and migrate to pulmonary interstitial and alveolar cavities. Afterwards, proinflammatory factors, such as inflammatory cytokines and proteases, are released and promote neutrophil-mediated lung injury [7] . In the later stage of ARDS, the injured lung is characterized by severe fibrosis and alveolar destruction and reconstruction [8] . The majority of ARDS/ALI patients show rapid disease progression because of this acute inflammatory process.

Various inflammatory mediators that activate the inflammatory cascade and induce secondary diffuse lung parenchymal injury are the primary causes of ARDS/ALI [9, 10] ; however, even low levels of inflammatory factors that do not contribute to the amplification of inflammation are associated with the onset of ARDS/ALI, suggesting their possible role as critical drivers of the disease. Therefore, inflammationrelated factors can potentially serve as reliable predictors of ARDS/ALI risk.

A previous study systematically reviewed the relationship between plasma biomarkers and ARDS onset and found that levels of Krebs von den Lungen-6 (KL-6), lactate dehydrogenase (LDH), the soluble receptor for advanced glycation end products (RAGE), and von Willebrand factor (vWF) were significantly correlated with ARDS incidence [11] ; however, the study did not investigate the inflammatory factors present in the pulmonary edema fluid, and conclusions were based on a relatively small number of studies for each inflammatory factor. Therefore, further validation of these putative associations is required. This study provided update results by analyzing recently pub-lished literature that investigated the relationships between specific inflammatory biomarkers and the onset of ARDS/ALI. Furthermore, these relationships were analyzed according to different characteristics.

We conducted the meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [12] .

We systematically searched the PubMed, EmBase, and Cochrane Central Register of Controlled Trials databases for publications up to July 2017 using the keywords "acute respiratory distress syndrome," "acute lung injury," "inflammation," "C-reactive protein," "interleukin," "tumour necrosis factor," "cytokines," "interferon," "transforming growth factor," and "risk factor." The search strategy used for the PubMed database is described in Supplementary information (searching strategy in PubMed). We restricted our search to reports published in English. We also included relevant articles cited as references of the studies.

Literature search and selection were independently performed by two researchers, and any inconsistencies were resolved by group discussion. A study was eligible for inclusion if the following criteria were met: (1) the study included patients with ARDS/ALI; (2) participants in the control group were not diagnosed with ARDS/ALI; (3) the primary outcomes of interest included Angiopoietin (ANG)-2, Interleukin (IL)-1β, IL-6, IL-8, IL-10, Plasminogen activator inhibitor (PAI)-1, and Tumor necrosis factor (TNF)-α, while the secondary outcomes included albumin, ANG-1, Clara cell secretory protein (CC16), C-reactive protein (CRP), endotoxin, granulocyte colonystimulating factor (G-CSF), intercellular cell adhesion molecule (ICAM), IL-2, IL-4, IL-12, KL-6, Lactate dehydrogenase (LDH), myeloperoxidase (MPO), nuclear factor (NF)-κβ, procalcitonin (PCT), protein C, RAGE, sE-selectin, surfactant protein (SP-D), transforming growth factor (TGF)-β1, tissue factor (TF), Tumor necrosis factor receptor (TNFR)-1, TNFR-2, vascular endothelial growth factor (VEGF), and vWF. Reviews, editorials, non-human studies, letters, and conference papers were excluded because of insufficient data.

The following parameters were extracted from the articles: first author, country, publication year, study design, sample size, and average age, gender, underlying disease of participants, patient disease status, method of ARDS/ALI diagnosis, specimen source, test time, and follow-up. The Newcastle-Ottawa Scale (NOS) was used to evaluate the methodolog-original article ical quality of each study [13] . The NOS is based on the following three subscales: selection of the study group (four categories), comparability of the groups (one category), and outcome assessment (three categories). Data extraction and quality assessment were conducted independently by two authors, and results were examined and adjudicated by an additional author who referred to the original study.

In this meta-analysis, the standard mean difference (SMD) and 95% confidence interval (CI) were determined to evaluate the effect of sample size across studies [14] . We pooled the SMDs for each inflammatory factor using a random effects model [15] . The I 2 statistic was used to assess heterogeneity of the SMDs across multiple studies [16] . Means and variances were estimated from medians and ranges as previously described [17] . A sensitivity analysis was performed by sequentially removing each individual study from the meta-analysis [16] . Meta-regression was also conducted for ANG-2, IL-1β, IL6, IL-8, IL10, PAI-1, and TNF-α based on sample size and mean age. Furthermore, stratified analyses were conducted based on sample size, mean age, patient status, and sample origin. Visual inspection of funnel plots from the Egger's [18] or Begg's test [19] was conducted to evaluate publication bias. All tests were two-tailed, and P-value < 0.05 was considered statistically significant. Data analyses were performed using STATA software (version 10.0; Stata Corporation, College Station, TX, USA). 

In this study, a total of 302 articles were retrieved from PubMed, 704 from EmBase, and 28 from the Cochrane Library. After removing duplicates, 851 articles passed the inclusion criteria in the meta-analysis. A total of 757 articles were excluded because they were considered irrelevant after scanning the titles and abstracts. Furthermore, articles that were considered to be unrelated based on full-text assessment (n = 5), a duplicate publication (n = 1), mortality-related studies (n = 18), studies with undesired outcomes (n = 4), and studies with control groups without ARDS/ALI risk (n = 3) were also excluded. Finally, 63 studies that studied a total of 6243 patients were included in our systematic review ( Fig. 1 ; ).

A total of 59 studies implemented a prospective design, while the remaining 4 studies employed a retrospective design. Most studies included patient groups with an average age ranging from 40 to 60 years. All participants enrolled in the included studies were at risk of ARDS/ALI, and the majority of samples were collected less than 1 day after study recruitment. All included studies employed standardized American-European Consensus Conference (AECC) criteria, Berlin definition of ARDS, lung injury score (LIS), and oxygenation index (PaO2/FiO2) for ARDS/ALI diagnosis. In earlier studies, there were no general criteria for defining ARDS, so the criteria were defined by the authors of each study. The NOS quality analysis for all studies returned scores ranging from 6 to 8, indicating a good overall quality of the included studies (Table 1) .

The relationship between ARDS/ALI and angiopoietin (ANG)-2 levels is presented in Fig. 2 . The overall standard mean difference (SMD) from six studies showed that ARDS/ALI patients had higher ANG-2 levels than those of unaffected individuals (SMD: 1.34; 95% CI: 0.59-2.10; P < 0.001); however, significant heterogeneity was detected (I 2 = 97.4%; P < 0.001). Sensitivity analysis showed that the conclusion did not change after sequential removal of each study (Supplementary information Table S1 ).

The relationship between ARDS/ALI and interleukin (IL)-1β levels is presented in Fig. 3 . The pooled SMD from 10 studies indicated that ARDS/ALI patients exhibited significantly higher IL-1β levels than those of the individuals without ARDS/ALI (SMD: 0.92; 95% CI: 0.20-1.64; P = 0.012). Although substantial heterogeneity was observed across all studies (I 2 = 93.1%; P < 0.001), the conclusion did not change 26 

Forest plot comparing IL-1β levels between ARDS/ALI patients and unaffected individuals after sequential exclusion of each study (Supplementary information Table S2 ).

The relationship between ARDS/ALI and IL-6 levels is shown in Fig. 4 . Overall results showed that ARDS/ALI patients had higher IL-6 levels than those of individuals in the population without ARDS/ALI (SMD: 0.66; 95% CI: 0.20 to 1.13; P = 0.005). Heterogeneity was observed at the same degree as the effect across the studies (I 2 = 93.6%; P < 0.001). Sensitivity analysis showed that the conclusion was not affected by the exclusion of any specific study from the pooled analysis (Supplement information Table S3 ).

The relationship between ARDS/ALI and IL-8 levels was analyzed in 14 studies, and results are shown in Fig. 5 . No significant differences in IL-8 levels were observed between ARDS/ALI patients and individuals of the population without ARDS/ALI (SMD: 0.61; 95% CI: -0.24-1.46; P = 0.159). Furthermore, substan-tial heterogeneity was detected (I 2 = 97.8%; P < 0.001). Based on sensitivity analysis, we excluded the study conducted by Calfee et al. [57] , which specifically included a large sample size of trauma patients. We concluded that ARDS/ALI were associated with higher IL-8 levels (SMD: 0.76; 95% CI: 0.11-1.40; P = 0.021) (Supplement information Table S4 ).

The relationship between ARDS/ALI and IL-10 levels was investigated in seven studies, and results are presented in Fig. 6 . We detected no significant differences in IL-10 levels between ARDS/ALI and non-ARDS/ALI patients (SMD: 1.10; 95% CI: -0.70-2.91; P = 0.231). Substantial heterogeneity was observed (I 2 = 98.3%; P < 0.001). Sensitivity analysis indicated that ARDS/ALI patients had higher IL-10 levels than those of non-ARDS/ALI patients when the study conducted by Roubinian et al. was excluded (Supplementary information Table S5 ) [82] . Forest plot comparing IL-6 levels between ARDS/ALI patients and unaffected individuals

Forest plot comparing IL-8 levels between ARDS/ALI patients and unaffected individuals

The relationship between ARDS/ALI and plasminogen activator inhibitor-1 (PAI-1) levels was investigated in seven studies, and results are presented in Fig. 7 . We detected no significant differences in PAI-1 levels between ARDS/ALI patients and non-ARDS/ALI individuals (SMD: 0.70; 95% CI: -0.03-1.43; P = 0.060). Substantial heterogeneity was observed (I 2 = 97.1%; P < 0.001). Sensitivity analysis showed that this result changed after excluding the study conducted by Calfee et al. (Supplementary information Table S6 ) [57] .

The relationship between ARDS/ALI and tumour necrosis factor (TNF)-α levels was investigated in 16 studies, and results are shown in Fig. 8 . Pooled results showed that ARDS/ALI patients had significantly higher TNF-α levels than those of individuals without ARDS/ALI (SMD: 0.98; 95% CI: 0.41-1.56; P = 0.001). Significant heterogeneity was detected across all in-cluded studies (I 2 = 94.0%; P < 0.001). These results did not change after sequential exclusion of any specific study (Supplementary information Table S7 ).

The correlations between ARDS/ALI and other inflammatory factors based on sample origin are summarized in Table 2 .

Overall, ARDS/ALI patients showed higher levels of albumin (SMD: 2. Forest plot comparing IL-10 levels between ARDS/ALI patients and unaffected individuals

Forest plot comparing PAI-1 levels between ARDS/ALI patients and unaffected individuals 3.36; P < 0.001), MPO (SMD: 2.58; P < 0.001), procalcitonin (PCT) (SMD: 0.41; P = 0.038), receptor for advanced glycation end products (RAGE) (SMD: 1.64; P = 0.031), sE-selectin (SMD: 0.55; P = 0.011), TF (SMD: 3.55; P < 0.001), and TNF receptor-2 (SMD: 3.82; P < 0.001) than unaffected individuals. ARDS/ALI was associated with lower IL-12 (SMD: -0.80; P < 0.001) levels in the blood. No other significant differences were observed between ARDS/ALI and non-ARDS/ALI patients.

A relatively large heterogeneity was observed among the studies included in our meta-analysis. We therefore performed a meta-regression analysis for ANG-2, IL-1β, IL-6, IL-8, IL-10, PAI-1, and TNF-α; results are presented in Supplementary information Figures S1-S14. Overall, sample size was determined to influence the association between PAI-1 levels and ARDS/ALI (P = 0.025); no other significant associations were observed. Subgroup analyses were also conducted based on sample size, mean age, patient status, and sample source (Table 3) . First, ARDS/ALI did not show a significant influence on ANG-2 levels when the mean age was < 60.0 years, and patients with ALI. Second, ARDS/ALI was not associated with IL-1β levels if the study sample size was ≥ 100, patients with ALI, or samples were collected from the BALF. Third, no significant associations were detected between ARDS/ALI and IL-6 levels when the study sample size was ≥ 100, the mean age was < 60.0 years, patients with ALI, and samples were collected from the blood. Fourth, ARDS/ALI were associated with higher IL-8 levels if the study sample size was < 100, patients had ARDS, or samples were collected from BALF. Fifth, ARDS/ALI were significantly associated with higher IL-10 levels when the study sample size was < 100, patients with ARDS, and samples were collected from the BALF. Sixth, ARDS/ALI patients showed signifi-K Meta-analysis 31 original article Fig. 8 Forest plot comparing TNF-α levels between ARDS/ALI patients and unaffected individuals cantly higher PAI-1 levels when the study sample size was < 100, patients with ARDS or ARDS/ALI, and samples were collected from the BALF. Finally, ARDS/ALI were not associated with TNF-α levels if the study sample size was ≥ 100, patients with ALI or ARDS/ALI. Although results of the Begg's tests showed no evidence of publication bias for ANG-2 (P = 0.707) and IL-8 (P = 0.827), results of Egger's test showed potential publication bias (P-value for ANG-2: 0.048; P-value for IL-8: 0.013). Conclusions did not change after correction using the trim and fill method [83] .

In our study, ARDS/ALI were found to be associated with higher levels of ANG-2, IL-1β, IL-6, and TNF-α, whereas no significant associations were detected between ARDS/ALI and IL-8, IL-10, and PAI-1 levels. Furthermore, serum levels of KL-6, MPO, RAGE, sEselectin, TF, and TNF receptor-2 were significantly higher in ARDS/ALI patients than in unaffected individuals; however, ARDS/ALI patients had lower IL-12 levels. The BALF concentrations of albumin, ANG-1, KL-6, MPO, TGF-β1, TF, and TNF receptor-1, were significantly higher in ARDS/ALI patients than in individuals without ARDS/ALI. In addition, ARDS/ALI were associated with lower levels of IL-12 and VEGF; however, heterogeneity among studies was substantial, and the amount of data available was insufficient. Therefore, more research is needed to verify the results of our meta-analysis.

Current treatment for ARDS/ALI consists of respiratory support and immunological treatment. Evidence suggests that the dynamic balance between proinflammatory and anti-inflammatory factors plays a key role in the pathogenesis and prognosis of ARDS/ALI [84] ; however, cytokine interactions are highly complex and difficult to study. When proinflammatory and anti-inflammatory factors are unbalanced, excess inflammatory cytokines are released, which in turn damage the lung tissues or even whole body tissues. Therefore, studies that investigate inflammatory factors present during the onset of ARDS/ALI can help elucidate the mechanisms underlying ARDS/ALI pathogenesis and serve as the basis for the development of new treatment approaches for ARDS/ALI. ANG-2 is a proinflammatory cytokine and a member of the vascular growth factor family. ANG-2 mainly promotes cell apoptosis and disrupts vascularization and can also act in conjunction with VEGF to promote neovascularization [85, 86] . The findings of the present study indicated that serum levels of ANG-2 were significantly higher in ARDS/ALI patients than in unaffected individuals. Similar to our current findings, serum levels of ANG-2 have been associated with other diseases, such as sepsis and pulmonary hypertension [87] . In particular, ANG-2 serum levels were associated with the onset of septic shock, and ANG-2 blood concentrations have been observed to increase during endothelial cell inflammation. Furthermore, elevated ANG-2 levels in the blood are known to promote vascular permeability and leakage; however, only a small number of studies have explored the re-32 Meta-analysis K original article ANG-1 Angiopoietin-1, CC16 Clara cell secretory protein, CRP C-reactive protein, G-CSF granulocyte colony-stimulating factor, ICAM intercellular cell adhesion molecule, IL-2 interleukin-2, LDH Lactate dehydrogenase, MPO myeloperoxidase, NF-κβ nuclear factor-κβ, PCT procalcitonin, RAGE receptor for advanced glycation end products, SP-D surfactant protein, TGF-β1 transforming growth factor-β1, TF tissue factor, TNFR-1 Tumor necrosis factor receptor-1, TNFR-2 Tumor necrosis factor receptor-2, VEGF vascular endothelial growth factor, vWF von Willebrand factor lationship between ANG-2 and ARDS/ALI incidence, and the overall results might have been altered by more recent findings from subsequent studies.

Our current results demonstrated that ARDS/ALI patients had significantly higher serum levels of IL-1β than individuals without ARDS/ALI. IL-1β is synthesized and released by mononuclear macrophages. It is recognized as the primary proinflammatory cytokine that triggers inflammation and is known to ex-ert multiple biological functions, such as promoting the activity of natural killer cells, increasing chemotaxis of macrophages and neutrophils, and regulating the immune response as an endogenous heat source [88, 89] . During infection or sepsis, IL-1β can destroy the blood-brain barrier and increase the risk of patient mortality. IL-1β has an inherent antagonist in the human body, IL-1ra, which can inhibit IL-1β activity by competitively binding to its receptor. One study included in this analysis showed that IL-1ra is significantly upregulated in ARDS patients [41] . Anakinra is an IL-1β antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis and other autoimmune diseases to reduce clinical symptoms and suppress joint destruction [90] . Determining whether this antagonistic effect can also be observed in ARDS patients is an interesting topic for future research. IL-6 is an acute inflammatory mediator that is released by various cell types. IL-6 is not expressed un- 34 Meta-analysis K original article der normal physiological conditions but is secreted upon stimulation by inflammatory factors [91] . Our study showed that IL-6 concentrations in the BALF were significantly higher in ARDS/ALI patients than in unaffected individuals. Consistent with these results, IL-6 is recognized as a reliable and objective indicator of local lung tissue damage.

IL-8 is a member of the C-X-C subfamily of chemokines and is produced by various cell types [92] . IL-8 plays a significant role in neutrophil chemotaxis and also inhibits neutrophil apoptosis. In response to local lung tissue injury, IL-8 specifically binds to its receptor, which in turn induces neutrophil aggregation and triggers the release of proteolytic enzymes that mediate inflammation and severe tissue damage. Our findings suggested that IL-8 concentrations are associated with ARDS/ALI incidence.

IL-10 is an anti-inflammatory cytokine that inhibits the secretion of TNF-α, IL-1, and IL-6 [93] . IL-10 can also suppress NF-κβ activity and regulate the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Our analysis suggested that IL-10 levels are correlated with ARDS/ALI incidence; however, the elevated IL-10 levels could have been caused by inflammation in the lungs.

PAI-1 is mainly secreted by vascular endothelial cells, and its production is a risk factor for thrombosis and atherosclerosis [94] . During ARDS pathogenesis, the coagulation fibrinolysis system is impaired, leading to disseminated intravascular coagulation. Increased PAI-1 levels may lead to local fibrin deposition in lungs. Our results support the idea that PAI-1 plays an important role in the development of ARDS. In addition, PAI-1 has been demonstrated to promote local formation of diseased connective tissue and has been used as an indicator of prognosis of ARDS patients.

The results of our study suggested a strong correlation between TNF-α concentrations in the BALF and ARDS incidence. TNF-α is considered as one of the most important proinflammatory factors in ARDS/ALI [95] . TNF-α is a multifunctional proinflammatory factor that stimulates the secretion of endothelin and nitric oxide by endothelial cells, promotes the expression of adhesion molecules by endothelial cells and leukocytes, and contributes to the progression of severe microcirculatory disorder. Therefore, TNF-α inhibition can potentially serve as an important approach for ARDS prevention and treatment.

The general objective of this study was to identify inflammatory factors that can serve as drug targets to reduce the incidence of ARDS/ALI. Multiple lines of evidence have suggested that proinflammatory cytokines participate in or trigger the inflammatory response in the lungs; however, currently available clinical data are insufficient to verify the correlations between the levels of proinflammatory factors and ARDS/ALI incidence.

Our current meta-analysis has several limitations First, results were based on other studies but not at the individual level. Second, the included studies showed significant heterogeneity, making it difficult to eliminate alternative explanations for the results, such as differences in the definition of ARDS/ALI, severity of disease, underlying diseases, sample collection times, and treatment strategies. Third, unpublished articles and articles written in other languages were not searched, which could have skewed the obtained results.

The results of our study indicated that ARDS/ALI are associated with elevated levels of ANG-2, IL-1β, IL-6, and TNF-α, but do not significantly affect IL-8, IL-10, and PAI-1 levels. Furthermore, ARDS/ALI incidence was also determined to be significantly associated with several other inflammatory factors; however, further studies using large sample sizes are required to verify our conclusions. Future studies should also measure the levels of inflammatory factors over time. Log transformation of the measures of inflammatory factors is recommended to obtain a normally distributed data, especially in studies with small sample sizes.

the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Mesenchymal stem cells and acute lung injury

Incidenceandoutcomesof acutelung injury

Extracorporealmembraneoxygenation for ARDSin adults

Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies

Difference in pulmonary permeability between indirect and direct acute respiratory distress syndrome assessed by the transpulmonary thermodilution technique: a prospective, observational, multi-institutional study

Postperfusion lung syndrome: respiratory mechanics, respiratory indices and biomarkers

Reactive oxygen molecule-mediated injury in endothelial and renal tubular epithelial cells in vitro

Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in anaged-mousemodelofsevereacuterespiratorysyndrome coronavirus infection

Vascular pharmacology of acute lung injury and acute respiratory distress syndrome

Biomarkers in acute lung injury

Plasma biomarkers for acute respiratory distress syndrome: asystematicreviewandmeta-analysis

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis

The interpretation of randomeffects meta-analysis in decision models

Cochrane handbook for systematic reviews of interventions. Version 5.1.0. London: The Cochrane Collaboration

Estimating the mean and variance from the median, range, and the size of a sample

Bias in meta-analysis detected by a simple, graphical test

Operating characteristics of a rank correlation test for publication bias

Fibrinolysis in critically ill patients

Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome

Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome

Studies on the role of tumor necrosis factor in adult respiratory distress syndrome

Serum antioxidants as predictors of adult respiratory distress syndrome in patients with sepsis

Role of selectins in development of adult respiratory distress syndrome

Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury

Soluble form of P-selectin in plasma is elevated in acute lung injury

Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS

Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome

Matrix metalloproteinases and TIMP in acute respiratory distress syndrome

Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema

Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome

Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients

Macrophage migration inhibitory factor and acute lung injury

Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis

Increased expression of functionally active membrane-associated tumor necrosis factor in acute respiratory distress syndrome

Maldonado A. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls

von Willebrand factor antigen as a prognostic marker in posttraumatic acute lung injury

Natural inhibitors of neutrophil function in acute respiratory distress syndrome

The regulation of interleukin-8 by hypoxia in human macrophages-a potential role in the pathogenesis of the acute respiratory distress syndrome (ARDS)

Cytokine balance in the lungs of patients with acute respiratory distress syndrome

Association between increased levels of IL-2 and IL-15 and outcome in patients with early acute respiratory distress syndrome

The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome

Surfactant protein A and D (SP-A, AP-D) levels in patients with septic ARDS

Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome

A prospective study of inflammation markers in patients at risk of indirect acute lung injury

A role for vascular endothelial growth factor in acute and resolving lung injury

Exhaled breath condensate nitrite and its relation to tidal volume in acute lung injury

Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome

Bronchoalveolar lavage fluids of ventilated patients with acute lung injury activate NF-kappaB in alveolar epithelial cell line: role of reactive oxygen/nitrogen species and cytokines

Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury

The clinical significance of serumandbronchoalveolar lavageinflammatory cytokines in patients at risk for acute respiratory distress syndrome

Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome

KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome

National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury

Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis

Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders

In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury

Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/ acute respiratory distress syndrome

Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome

Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma?

Tracheobronchial markers of lung injury in smoke inhalation victims

Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acuterespiratorydistresssyndrome

Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury

Relationship between the expression of Toll-like receptor 2 and 4 in mononuclear cells and postoperative acute lung injury in orthotopic liver transplantation

Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study

Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury

Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial

Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients

Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis

Plasma protein levels are markers of pulmonary vascular permeability and degreeof lung injury incritically ill patientswithor atriskfor acute lung injury/acute respiratory distress syndrome

High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome

Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients

Impact of serum high-mobility group box 1 protein elevation on oxygenation impairment after thoracic aortic aneurysm repair

Soluble endothelial selectin in acute lung injury complicated by severe pneumonia

Alveolar fibrocyte percentage is an independent predictor of poor outcome in patients with acute lung injury

Bronchoalveolar activation of coagulation and inhibition of fibrinolysis during ventilator-associated lung injury

Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients

Bronchoscopy-derivedcorrelatesoflunginjury following inhalational injuries: a prospective observational study

Serial inflammatory biomarkers of the severity, course and outcome of late onset acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new-onset fever

Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions

Trim and fill: a simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis

Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS

Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance

The levels of angiopoietin-2 in patients with acute respiratory distress syndrome and its value on prognosis

Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis

Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome

Acute lung injury: a clinical and molecular review

TheuseofIL-1receptorantagonist (anakinra) in idiopathic recurrent pericarditis: a narrative review

The role of apoptosis in the pathophysiology of acute respiratory distress syndrome (ARDS): an up-to-date cellspecific review

Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia

Novel activity of an anti-inflammatory cytokine: IL-10 prevents TNFalpha-induced resistance to IGF-I in myoblasts

Plasminogen activator inhibitor-1 controls vascular integrity by regulating VE-cadherin trafficking

Tumor necrosis factor (TNF) and lymphotoxinalpha (LTA) single nucleotide polymorphisms: importance in ARDS in septic pediatric critically ill patients